Skip to main content
. 2018 Apr 3;361:k1180. doi: 10.1136/bmj.k1180

Table 2.

Unadjusted incidence rates of branded drug product switchbacks for authorized generic compared with generic switchers per 100 person years of follow-up

Drug product Overall (95% CI) Authorized generic switchers (95% CI) Generic switchers (95% CI) Incidence rate difference (95% CI) Incidence rate ratios (95% CI)
Alendronate tablets 3.8 (3.4 to 4.2) 3.2 (2.4 to 4.2) 3.9 (3.5 to 4.3) −0.7 (−1.7 to 0.3) 0.82 (0.61 to 1.10)
Amlodipine tablets 4.8 (4.6 to 5.1) 4.3 (4.0 to 4.7) 5.2 (4.9 to 5.6) −0.9 (−1.4 to −0.4) 0.83 (0.75 to 0.92)
Amlodipine-benazepril capsules 17.8 (17.0 to 18.6) 12.8 (10.6 to 15.4) 18.3 (17.4 to 19.1) −5.4 (−7.9 to −3.0) 0.70 (0.58 to 0.84)
Escitalopram tablets 13.8 (13.2 to 14.5) 13.4 (12.7 to 14.1) 15.6 (14.1 to 17.2) −2.2 (−3.9 to −0.5) 0.86 (0.77 to 0.96)
Glipizide extended release tablets 7.8 (7.1 to 8.5) 6.5 (5.7 to 7.3) 9.5 (8.4 to 10.7) −3.0 (−4.4 to −1.7) 0.68 (0.57 to 0.81)
Quinapril tablets 4.7 (4.4 to 5.2) 3.2 (2.7 to 3.7) 6.0 (5.5 to 6.7) −2.9 (−3.7 to −2.1) 0.52 (0.43 to 0.63)
Sertraline tablets 9.2 (8.8 to 9.6) 8.1 (7.5 to 8.7) 10.1 (9.5 to 10.7) −2.0 (−2.8 to −1.2) 0.80 (0.73 to 0.88)
Overall 8.2 (8.1 to 8.4) 7.4 (7.2 to 7.6) 8.9 (8.6 to 9.1) −1.5 (−1.8 to −1.1) 0.83 (0.80 to 0.87)